Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regorafenib and SIR-Spheres in Refractory mCRC
NCT02195011Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Jul 2014
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of regorafenib in colorectal cancer (CRC) (2 arms), sponsored by SCRI Development Innovations. Primary endpoint: Number of Participants With Treatment-Related Adverse Events and Serious Adverse Events at 15 months. Started Jul 2014; status: completed.
02
Drugs
regorafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT02195011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02195011.